1. Home
  2. OCUL vs KRP Comparison

OCUL vs KRP Comparison

Compare OCUL & KRP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OCUL
  • KRP
  • Stock Information
  • Founded
  • OCUL 2006
  • KRP 2013
  • Country
  • OCUL United States
  • KRP United States
  • Employees
  • OCUL N/A
  • KRP N/A
  • Industry
  • OCUL Biotechnology: Pharmaceutical Preparations
  • KRP Oil & Gas Production
  • Sector
  • OCUL Health Care
  • KRP Energy
  • Exchange
  • OCUL Nasdaq
  • KRP Nasdaq
  • Market Cap
  • OCUL 957.3M
  • KRP 1.1B
  • IPO Year
  • OCUL 2014
  • KRP 2017
  • Fundamental
  • Price
  • OCUL $7.31
  • KRP $12.55
  • Analyst Decision
  • OCUL Strong Buy
  • KRP Hold
  • Analyst Count
  • OCUL 10
  • KRP 5
  • Target Price
  • OCUL $16.22
  • KRP $17.80
  • AVG Volume (30 Days)
  • OCUL 1.9M
  • KRP 845.6K
  • Earning Date
  • OCUL 05-06-2025
  • KRP 05-08-2025
  • Dividend Yield
  • OCUL N/A
  • KRP 13.68%
  • EPS Growth
  • OCUL N/A
  • KRP N/A
  • EPS
  • OCUL N/A
  • KRP N/A
  • Revenue
  • OCUL $63,723,000.00
  • KRP $310,652,668.00
  • Revenue This Year
  • OCUL $13.32
  • KRP $12.12
  • Revenue Next Year
  • OCUL $13.13
  • KRP $3.41
  • P/E Ratio
  • OCUL N/A
  • KRP N/A
  • Revenue Growth
  • OCUL 9.03
  • KRP 13.72
  • 52 Week Low
  • OCUL $4.06
  • KRP $10.98
  • 52 Week High
  • OCUL $11.78
  • KRP $17.07
  • Technical
  • Relative Strength Index (RSI)
  • OCUL 51.39
  • KRP 43.13
  • Support Level
  • OCUL $6.94
  • KRP $11.77
  • Resistance Level
  • OCUL $7.83
  • KRP $12.35
  • Average True Range (ATR)
  • OCUL 0.72
  • KRP 0.66
  • MACD
  • OCUL 0.07
  • KRP -0.02
  • Stochastic Oscillator
  • OCUL 74.57
  • KRP 46.80

About OCUL Ocular Therapeutix Inc.

Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.

About KRP Kimbell Royalty Partners Common Units Representing Limited Partner Interests

Kimbell Royalty Partners LP owns and acquires mineral and royalty interests in oil and natural gas properties throughout the United States. The company's basins and producing regions include areas of interest in the Permian Basin, Mid-Continent, Terryville/Cotton Valley/Haynesville, Appalachian Basin, Eagle Ford, Bakken/Williston Basin, and DJ Basin/Rockies/Niobrara. Its revenues are derived from royalty payments received from operators based on the sale of oil, natural gas and NGL production, as well as the sale of NGLs that are extracted from natural gas during processing.

Share on Social Networks: